
2025 EU HTA: Launching a New Era in Joint Clinical Assessments
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the
What is NTAP The New Technology Add-On Payment (NTAP) is a reimbursement program under the
In the competitive and resource-constrained world of biotechnology, achieving market access and reimbursement is critical.
The implementation of the Joint Clinical Assessment (JCA) in the European Union represents a notable
On July 4, 2024, the Bundestag (German Parliament) passed significant amendments to the country’s drug
What you need to know about confidential discounts and net prices in EU-5 In the
Justin Stindt Consultants est une société de conseil à croissance rapide qui offre des services de conseil en stratégie et en accès au marché à des clients de premier plan dans le domaine pharmaceutique, biotechnologique et des dispositifs médicaux. Nous sommes présents en Europe et aux États-Unis.
© 2025 Justin Stindt Consultants une marque de Justin Stindt Consulting